For Immediate Release Contact: Lesia Golden OHC Marketing Department 513-751-2273 ext. 10204 lesia.golden@usoncology.com Cincinnati, Aug. 9, 2017 — OHC, the region’s premier source of treatment for nearly every form of cancer and complex blood... Read More

A Summary Review of Multiple Myeloma

By Edward A. Faber, DO, MS, OHC; Real World Health Care, December 13, 2017

Multiple Myeloma, a rare cancer of the plasma cells, has 30,300 new cases diagnosed each year. With more than 12,650 deaths annually, a quick review is timely: Causes Although exact causes remain unknown, scientists have made progress in... Read More

Phase I Clinical Trial for Patients with Muscle Invasive Bladder Cancer

By David M. Waterhouse, MD, MPH, medical oncologist and co-director of research, OHC

OHC’s Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-State to participate in innovative studies which include targeted and immunotherapies. In order to obtain FDA approval, all drugs... Read More

Bladder Cancer in Review

Benjamin T. Herms, MD, Medical Oncologist and Hematologist with OHC

Bladder cancer – the fourth most common cancer in the United States among men and ninth among women – arises in the lining of the bladder and is highly treatable. With 50,000 new cases diagnosed each year, a quick review is timely: Risk Factors ... Read More

Although melanoma accounts for only 1 percent of all skin cancers, the American Cancer Society estimates that about 76,380 new melanomas will be diagnosed in 2016, and more than 10,000 persons will die of the disease. As you know, skin cancer is the... Read More

Phase I Clinical Trials Offer Patients More Benefits Than Ever Before

By David M. Waterhouse, MD, MPH, medical oncologist and co-director of research, OHC

The OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-state to participate in innovative studies which include targeted therapies. OHC’s history of successful participation in... Read More

OHC Gynecology Oncology Clinical Trial Update

Cynthia Chua, M.D., OHC Principal Investigator, Gynecology Oncology Clinical Trials

The OHC Department of Clinical Research is offering a clinical trial, GYN41, utilizing Doxil with or without Trabectedin (YONDELIS), a DNA-binding agent that inhibits inducible transcription. This trial is enrolling advanced relapsed patients with... Read More

Update on Cervical Cancer Screening Guidelines

Sarah Wilson, MSN, APRN, OHC Gynecology Oncology Advanced Practice Provider

According to the American Cancer Society’s estimates for cervical cancer in the United States for 2016: About 12,990 new cases of invasive cervical cancer will be diagnosed. About 4,120 women will die from cervical cancer. Historically,... Read More

OHC Research Clinical Trial Updates

OHC

OHC is offering two new clinical trials. To view our entire research clinical trial menu, please click here. 1) Lynch Syndrome Trial This is an investigational trial that runs analyses on patients’ blood, saliva, and tumor tissue to determine if... Read More

Cancer Treatment Advances: A Year In Review - OHC

Summary by E. Randolph Broun, MD, President & Chairman of the Board, OHC; Original article by Megan Garlapow, PhD, ObR November 2017

We have seen significant progress in how cancer is treated this last year. Individualized and personalized therapy has revolutionized the treatment plan for many cancer types. Nivolumab, a new immunotherapy drug used to treat advanced non-squamous,... Read More